The model's full reasoning — Q3 2017 call → NOWe need to evaluate two gates based on the transcript. Gate 1: Is the company talking about how demand is off the charts? And do the numbers support that claim? The transcript mentions product sales up 71% for the quarter, 73% year-to-date. That is strong growth. But "off the charts" is a strong phrase. The transcript says "product sales for the 2017 third quarter increased by 71% in the prior year" and "up 73% for the nine months year-to-date." That is high growth. However, the question asks if they are talking about demand being off the charts. They talk about "solid third quarter financial performance" and "star goes to growing product sales." They don't explicitly say "off the charts." But the growth is high. The gate says "is the company talking about how demand is off the charts? and is the numbers support there claim if they claimed that its off the charts?" So we need to see if they claim demand is off the charts. They don't use that phrase. They say "product sales increased by 71%." That is strong but not necessarily "off the charts." Also, they mention "increased demand for our enzymes across a broad customer base." So they talk about increased demand. But "off the charts" is an exaggeration. The gate might be interpreted as whether they are claiming exceptionally strong demand. They do say "step change growth in product sales." That is strong. But the gate specifically says "off the charts." I think we need to be strict. The transcript does not use that phrase. Also, the numbers support strong growth but not necessarily "off the charts" in a hyperbolic sense. However, the gate might be asking if they are talking about demand being very high and if numbers support it. They are talking about increased demand and strong growth. But the phrase "off the charts" is not used. I'll consider that they are talking about strong demand, but not necessarily "off the charts." The gate says "is the company talking about how demand is off the charts?" That is a specific claim. They don't say that. So Gate 1 might be NO. But let's read the transcript carefully. They say "product sales were up 71% for the quarter and up 73% for the nine months year-to-date." That is very high. They also say "increased demand for our enzymes across a broad customer base." So they are talking about strong demand. But "off the charts" is an idiom meaning extremely high.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TRP | TC Energy Corporation | Q1 2024 | 2024-05-03 | B |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C |
| ONON | On Holding AG | Q2 2022 | 2022-08-16 | A |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | A |
| CPAC | Cementos Pacasmayo S.A.A. | Q4 2021 | 2022-02-15 | C |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
ONON · Q2 2022 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows the company describing demand as exceptionally strong through record growth (67% YoY, CHF 291.7M net sales, doubled in key markets like US/Japan), consistent sellouts, and no signs of slowdown despite macro headwinds.
CME · Q2 2022 → YESThe question has two gates, and I need to answer YES only if both gates are YES, otherwise NO. And answer with exactly YES or NO. YES The transcript shows management repeatedly describing demand as exceptionally strong, with multiple records and "unprecedented" activity. Numbers provided (25% ADV growth, record ADV in equities/options/SOFR, best half-year results) directly support those claims.
CPAC · Q4 2021 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES ``` The transcript shows the company describing demand as "unprecedented" and "off the charts" through record volumes (2.6M tons in 2019 to 3.6M in 2021, ~38-40% growth) and revenue/EBITDA surges (49.